An interesting target for a more selective medical treatment of PDH would be the receptor for ACTH: the Gsα-protein-coupled melanocortin 2 receptor (MC2R) (Mountjoy et al. 1992). The gene discussed is POMC; the disease is pyruvate dehydrogenase deficiency.